Employee Benefits News examines legal developments that impact the employee benefits and executive compensation employers provide, including federal and state legislation, rules from federal...
Anthem Inc. and Express Scripts Inc. defeated a proposed class action challenging their drug pricing methods under federal benefits, racketeering, and health discrimination law.
The companies couldn’t be liable under the Employee Retirement Income Security Act for allegedly setting high drug prices, because they weren’t acting as ERISA fiduciaries when they set those prices, a federal judge ruled Jan 8. The judge also rejected claims by HIV-positive patients who said the high drug prices were discriminatory under the Affordable Care Act. He dismissed all claims in the 17-count lawsuit, although he gave the patients and health plans that filed suit another chance to litigate.
The ruling is the latest chapter in the $15 billion battle between health insurer Anthem and pharmacy benefit manager (PBM) Express Scripts. Anthem sued Express Scripts in 2016, claiming the company was overcharging for prescription drug benefits in violation of the parties’ agreement. That case remains pending after a federal judge dismissed some of Express Scripts’ counterclaims against Anthem.
Both cases stem from a 2009 deal in which Express Scripts agreed to provide prescription drug services for Anthem health plans and Anthem sold Express Scripts three PBM companies for more than $4 billion. The patients who filed this lawsuit say Express Scripts paid a multibillion-dollar premium for the PBM companies and in turn began significantly overcharging Anthem patients for prescription drugs.
Anthem has since announced plans to start its own PBM unit and signed a five-year deal with Express Scripts’ biggest competitor, CVS Health Corp.
The decision focused on whether Anthem and Express Scripts qualified as ERISA fiduciaries of the relevant health plans, and thus whether they could be liable for fiduciary breach.
The patients said Express Scripts was an ERISA fiduciary because the company’s deal with Anthem gave it discretion to set drug prices and therefore to determine what compensation it received from ERISA plan assets. The judge disagreed, saying service providers don’t act as fiduciaries when they merely follow the terms of a contract.
The patients also argued for Anthem’s fiduciary status, saying the company exercised fiduciary discretion in creating this deal with Express Scripts. The judge again disagreed, saying Anthem was making business decisions—and not plan administration decisions—when it contracted with Express Scripts and negotiated drug pricing terms.
Finally, the judge rejected the idea that the pricing terms violated the ACA’s nondiscrimination rules. The HIV-positive patients who advanced this argument didn’t show they paid a disproportionately high amount for HIV-related drugs compared with other drugs, the judge said.
In so ruling, the judge declined to decide whether the ACA’s nondiscrimination rules, which prohibit health-based discrimination against people with disabilities, allows for a claim based on the “disparate impact” a policy could have on people with disabilities.
Judge Edgardo Ramos of the U.S. District Court for the Southern District of New York wrote the decision.
The patients are represented by Keller Rohrback LLP, Consumer Watchdog, Whatley Kallas LLP, and Neubert Pepe & Monteith PC. Express Scripts is represented by Quinn Emanuel and Steptoe & Johnson LLP. Anthem is represented by White & Case LLP and Nelson Mullins Riley & Scarborough.
The case is In re Express Scripts, Inc. , 2018 BL 5645, S.D.N.Y., No. 1:16-cv-03399-ER, order granting motion to dismiss 1/5/18 .
To contact the reporter on this story: Jacklyn Wille in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Jo-el J. Meyer at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)